Study limitation reported by the research below: “The impact flag 'practice changing' is applied cautiously — the CF-GMDI is a novel research metric not yet in clinical use, but its superiority over alpha diversity for detecting ETI-driven microbiome shifts may influence trial design and endpoint selection.”